Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
about
Systematic review of dasatinib in chronic myeloid leukemiaImportance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian settingResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsDissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerationsSecondary mutations as mediators of resistance to targeted therapy in leukemiaInhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cellsTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinibDasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibNCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaChronic myelogenous leukemia: treatment and monitoring.Monitoring response and resistance to treatment in chronic myeloid leukemia.Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.The role of dasatinib in the management of chronic myeloid leukemiaMoving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitorsOutcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureCytogenetic study in CML.Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML.In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemiaManagement of imatinib-resistant patients with chronic myeloid leukemia.Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureThe predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.Treatment of chronic myeloid leukemia when imatinib fails.
P2860
Q24596026-378D04AB-FE7A-4A8D-BD85-DB07BE981C74Q27008389-43D74DBB-E4A5-4D19-89F5-D9140C309C95Q27028181-00767D5A-33F9-4DD8-AC0D-6F144AA3500AQ27851628-105AB556-6E26-4FF8-8652-407DB925ACA9Q28079372-B53DF762-07DA-473F-9416-DAB1CF05956BQ28087213-5FA81686-3935-4374-AA3C-8EB5BB091668Q28545195-E245896B-2382-45B5-9A21-BC522262B1ABQ30242015-9EF19688-5CE0-4D14-9C70-226FA617115FQ33390293-7ABCC311-9C4C-4CE3-A423-6624FE6FBA57Q33391185-0E6F7FAE-1947-41CD-8126-AF475E780F4EQ33397085-0D5AD22A-CAA7-4836-9298-DCF849E3C6FBQ33399101-8D2DE65F-6B19-4ABF-85E7-4B20006D3A74Q33401360-0125B2E3-F44B-4A8D-8331-2906187E7D28Q33402939-C96EA816-7885-4860-A669-9630BC0CE3B6Q33414487-D46EB624-6BD8-4A39-BE5F-8E5E39AED5FAQ33903030-2D037DA6-8C5F-4F1A-9ABE-F4D40C3FBFB2Q34046343-76D02037-DEA5-4A31-990A-78F269E185D5Q34121339-3DDE7781-68E7-4AAA-B33B-A6F42FA937C5Q34210528-7F3F0088-D82A-4604-A5FA-FDBFA587679EQ34522789-926A1283-B130-4DC1-8E50-DA55D8F8FF8CQ34617628-8DDD1224-A7E1-485F-A26D-DAF3ECBBB15DQ34761663-0E70054C-4B15-46F4-ABEB-27FFF08AF01FQ34763374-D4E3818C-5F6D-4BAE-8F6B-D21CC6157CF0Q35083184-99C6A1B8-3A93-4DA8-8301-AE9DCF6705B6Q35087994-D5A1D1C4-F82B-438F-A383-6EC9BE3FE80BQ35117747-B68EF2DC-50D9-4E73-B8DD-C3B23E19C97DQ35595870-2C0191D3-FA59-4EBF-BAA7-BAA4CE7AE222Q35596200-60ABFE98-1C2B-4966-9551-9563FFE2B2F2Q35838636-997415D2-D967-4228-8DDB-89FD930989D2Q35903385-B2C38E1E-9383-465B-B50F-CEF0A108079AQ36093137-A5352AC2-5072-43D4-A029-7B8816BFFEA3Q36364850-C4D1C7A9-9C71-4206-ACE6-8BBC9167138EQ36450182-3D15714F-B8EB-4945-A64F-002C76F6B5FCQ36462473-6243B4EC-F9AC-44A9-95FC-71A720909FB3Q36776423-9009070E-8868-47DA-A891-9B73C725AE73Q37027759-3B9E015C-C957-459B-A5A1-1110E4F0D484Q37714627-1942C224-E4C7-479C-8734-D2BC600F7DE4Q37763106-39869E39-B7CA-45AF-BB4B-A645B7677613Q37797981-BD4A45A8-F31F-4DC8-9377-14BC6547C247Q37827875-8D461198-E793-4A5D-BEB1-A761BCE9BF33
P2860
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dasatinib or high-dose imatini ...... mized phase 2 study (START-R).
@en
Dasatinib or high-dose imatini ...... of a randomized phase 2 study
@nl
type
label
Dasatinib or high-dose imatini ...... mized phase 2 study (START-R).
@en
Dasatinib or high-dose imatini ...... of a randomized phase 2 study
@nl
prefLabel
Dasatinib or high-dose imatini ...... mized phase 2 study (START-R).
@en
Dasatinib or high-dose imatini ...... of a randomized phase 2 study
@nl
P2093
P2860
P50
P356
P1433
P1476
Dasatinib or high-dose imatini ...... omized phase 2 study (START-R)
@en
P2093
Eric Bleickardt
Hagop Kantarjian
Jerzy Holowiecki
Jorge Cortes
Neil P Shah
Ricardo Pasquini
Saengsuree Jootar
Timothy Hughes
P2860
P304
P356
10.1002/CNCR.24504
P407
P577
2009-09-01T00:00:00Z